Revance to Release Second Quarter 2022 Financial Results on Tuesday, August 9, 2022
Revance Therapeutics, Inc. (NASDAQ: RVNC) is set to release its Q2 2022 financial results on August 9, 2022, after market close.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Conference Call Scheduled for
Individuals interested in listening to the conference call may do so by registering via the webcast link in the investor relations section of the company's website at: www.revance.com.
To access the call by phone, please use this registration link, and you will be provided with dial in details. To avoid delays, we encourage participants to dial into the conference call fifteen minutes ahead of the scheduled start time. A webcast replay will be available in the investor relations section on the company's website for 30 days following the completion of the call.
About
Revance is a commercial stage biotechnology company focused on innovative aesthetic and therapeutic offerings, including its next-generation, long-acting neuromodulator product, DaxibotulinumtoxinA for Injection. Revance has successfully completed Phase 3 clinical programs for DaxibotulinumtoxinA for Injection in glabellar (frown) lines, for which the company is currently pursuing
"
Resilient Hyaluronic Acid® and RHA® are trademarks of
BOTOX® is a registered trademark of
View source version on businesswire.com: https://www.businesswire.com/news/home/20220802005975/en/
Media
Media@revance.com
Investors
jessica.serra@revance.com
or
laurence@gilmartinir.com
Source: